Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Object: Bioluminescence imaging (BLI) offers a rapid and accurate means for longitudinal study of tumor cell growth and response to therapy in rodent models. Because this technology has only recently come into use in the field of small animal imaging, applications in this area have been limited. In the current study we have applied BLI to the analysis of clinically relevant issues involving use of the DNA methylating agent temozolomide (TMZ) in a mouse model. Methods: An invasive glioblastoma multiforme xenograft was modified for BLI via transduction with a luciferase-encoding lentivirus. Supratentorial tumors were established in athymic nude mice that were subsequently assigned randomly to control and TMZ treatment groups, and the extent of intracranial tumor was monitored using BLI. Results: In an experiment designed to compare the extent of antitumor effect between a single high-dose TMZ treatment and a protracted low-dose TMZ regimen, BLI revealed the protracted regimen as having superior antitumor effect, and this interpretation was consistent with results from a survival comparison between the two TMZ treatment groups. In a second experiment designed to assess the utility of BLI for testing therapies against recurrent glioblastoma multiforme, mice with intracranial tumors were retreated with TMZ at a time when BLI monitoring revealed tumor regrowth following initial TMZ treatment, and retreatment was successful in providing additional survival benefit. Conclusion: The results of these experiments indicate that BLI monitoring can be used as a surrogate for predicting survival benefit from TMZ treatment, permits early determination of relative survival benefit associated with distinct TMZ therapeutic regimens, and offers a means of investigating secondary/salvage therapy efficacy following tumor regrowth from initial therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Cited by
Carlson, B. L., Pokorny, J. L., Schroeder, M. A., & Sarkaria, J. N. (2011) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1416s52 · Cited by 227
“Similar studies have been performed to examine tumor responses to, e.g., radiation, temozolomide, everolimus, and viral therapy (Sarkaria et al., 2006; Dinca et al., 2007, 2008; Liu et al., 2007; Allen et al., 2008; Yang et al., 2008; Carlson et al., 2009; Clarke et al., 2009; Kitange, 2009a,b).”
BackgroundSelf-citationDirect In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells
Lathia, J. D., Gallagher, J., Myers, J. T., Li, M., Vasanji, A., McLendon, R. E., Hjelmeland, A. B., Huang, A. Y., & Rich, J. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024807 · Cited by 158
Renfrow, J. J., Soike, M. H., West, J. L., Ramkissoon, S. H., Metheny-Barlow, L., Mott, R. T., Kittel, C. A., D’Agostino, R. B., Tatter, S. B., Laxton, A. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72290-2 · Cited by 45
Self-citation
Metadata
- Authors
- Dinca, E. B., Sarkaria, J. N., Schroeder, M. A., Carlson, B. L., Voicu, R., Gupta, N., Berger, M. S., & James, C. D.
- Venue
- Journal of Neurosurgery
- Published
- 2007-09
- Volume
- 107
- Issue
- 3
- Pages
- 610-616
- ISSN
- 0022-3085 (ISSN-L)
- OpenAlex
- W2060360125
- Cited by
- 79
- References
- 1
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. https://app.cochat.ai/papers/10.3171/jns-07/09/0610
- The paper
- Dinca, E. B., Sarkaria, J. N., Schroeder, M. A., Carlson, B. L., Voicu, R., Gupta, N., Berger, M. S., & James, C. D. (2007). Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy. Journal of Neurosurgery. https://doi.org/10.3171/jns-07/09/0610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.